Harman

Harman at a Glance

Harman — also spelled harmane and known chemically as 1-methyl-β-carboline — is one of the simplest members of the β-carboline (harmala) alkaloid family, the same structural group as harmine and harmaline. Unlike its ayahuasca-associated relatives, harman is rarely encountered as a deliberately-taken substance. It matters instead because it is everywhere at low levels: it is formed when foods are cooked, is present in coffee and tobacco smoke, and circulates endogenously in human plasma and brain ^{3,4Reference 3Herraiz T · 2004Relative exposure to beta-carbolines norharman and harman from foods and tobacco smokeView study →Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →}.

That makes the harman story less about what people take and more about what they are continuously and involuntarily exposed to. As a group, β-carbolines are reversible, MAO-A-selective inhibitors ^{1Reference 1Kim H et al. · 1997Inhibition of monoamine oxidase A by beta-carboline derivativesView study →}, so harman is usually discussed as a widespread, low-dose environmental and dietary monoamine-oxidase inhibitor rather than a drug. Research interest has clustered around three things: its weak MAO-A inhibition, its epidemiological associations with the movement disorders essential tremor and Parkinson’s disease ^{7,8,9Reference 7Louis ED et al. · 2002Elevation of blood beta-carboline alkaloids in essential tremorView study →Reference 8Louis ED et al. · 2020ObservationalBlood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe IslandsView study →Reference 9Louis ED et al. · 2014Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s diseaseView study →}, and its co-mutagenic chemistry when meat and tobacco are pyrolysed ^{5,6Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →Reference 6Oda Y et al. · 2006Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymesView study →}.

Its moderate toxicity flag reflects that combination — MAO inhibition at higher exposure, a consistent (if unproven-as-causal) link to tremor, and genuine genotoxic behaviour on pyrolysis — set against the reassurance that ordinary dietary levels are very low.

Harman as a Dietary & Endogenous β-Carboline

The compound-defining fact about harman is its ubiquity at trace levels, from three overlapping sources.

Endogenous. Harman and its des-methyl analogue norharman are normal constituents of the human body, detectable in plasma, platelets, urine and brain tissue; they form in vivo, plausibly from the condensation of tryptophan-derived amines with small aldehydes (a Pictet–Spengler reaction) ^{4Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →}. This is why harman is often described as a candidate endogenous signalling molecule rather than purely a xenobiotic ^{10Reference 10Abu Ghazaleh H et al. · 2015Harmane: an atypical neurotransmitter? Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/25625221/View study →}.

Dietary (thermal formation). Cooking generates harman. It is produced during the heating and pyrolysis of protein-rich foods — fried and grilled meat and fish, meat extracts — and is present in coffee brews, roasted foods and alcoholic drinks ^{3,4Reference 3Herraiz T · 2004Relative exposure to beta-carbolines norharman and harman from foods and tobacco smokeView study →Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →}. Levels rise with cooking temperature and time, tracking the same chemistry that produces heterocyclic aromatic amines.

Environmental (tobacco). Tobacco smoke is a concentrated source: harman is present in mainstream cigarette smoke at roughly 360–2,240 ng per cigarette, and at even higher levels in sidestream smoke ^{5Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}. Because β-carbolines inhibit MAO, this dietary-and-smoke exposure is one proposed reason smokers show reduced brain MAO activity, an effect studied for its links to dopamine signalling and to the reinforcing effects of tobacco ^{2Reference 2Saro G et al. · 2025Monoamine oxidase inhibitors present in tobacco modulate dopamine balance via the dopamine transporterView study →}.

The practical framing: harman is not a supplement or a drug you choose to take — it is a background exposure shared by nearly everyone, with smokers and heavy consumers of well-cooked meat at the higher end.

The Co-Mutagen & Tryptophan-Pyrolysis Angle

Harman’s most distinctive toxicological property is that it is a co-mutagen. On its own, harman is only weakly mutagenic in standard bacterial assays; its significance is that it amplifies the mutagenicity of other compounds and can itself be bioactivated into genotoxic metabolites.

Harman and norharman are tryptophan-pyrolysis products — they appear alongside the heterocyclic aromatic amines generated when protein-rich food is charred or overcooked, and in cigarette-smoke condensate ^{5Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}. In the body, norharman reacts with aromatic amines (such as aniline and toluidine) to form aminophenyl-β-carbolines; these adducts are then activated by human N-acetyltransferases and cytochrome-P450 enzymes into directly-genotoxic metabolites that damage DNA ^{6Reference 6Oda Y et al. · 2006Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymesView study →}. Harman participates in the analogous chemistry to form aminophenylharman. This “co-mutagen” behaviour — turning otherwise weak or non-mutagenic partners into DNA-damaging species — is the mechanistic core of the concern about β-carbolines in cooked foods and tobacco smoke.

This is a chemistry-and-cell story, not a demonstrated human cancer risk from harman specifically; but it is why harman carries genotoxic caveats that a typical trace plant alkaloid does not.

What It's Used For

Harman’s pharmacology is modest and, importantly, mostly studied at exposures far above ordinary dietary levels, or as epidemiological associations rather than controlled dosing. The evidence divides into a mechanistic enzyme/receptor story and a population-level neurological one.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Note these are research signals and associations, not established human uses — harman is not taken therapeutically.

01MAO-A Inhibition (Dietary/Environmental)Shaky40%β-carboline enzyme assays + smoking/MAO evidence; harman weaker than harmine ^{1,2Reference 1Kim H et al. · 1997Inhibition of monoamine oxidase A by beta-carboline derivativesView study →Reference 2Saro G et al. · 2025Monoamine oxidase inhibitors present in tobacco modulate dopamine balance via the dopamine transporterView study →}

02Essential-Tremor & Parkinson AssociationShaky38%Multiple human case-control blood studies (Louis group) — correlational ^{7,8,9Reference 7Louis ED et al. · 2002Elevation of blood beta-carboline alkaloids in essential tremorView study →Reference 8Louis ED et al. · 2020ObservationalBlood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe IslandsView study →Reference 9Louis ED et al. · 2014Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s diseaseView study →}

03Co-Mutagenicity / GenotoxicityShaky34%Bacterial + human-enzyme bioactivation assays; smoke/cooked-food quantification ^{5,6Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →Reference 6Oda Y et al. · 2006Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymesView study →}

04Imidazoline / Benzodiazepine BindingShaky26%In-vitro/ex-vivo receptor binding; endogenous-ligand candidacy ^{10,11Reference 10Abu Ghazaleh H et al. · 2015Harmane: an atypical neurotransmitter? Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/25625221/View study →Reference 11Saano V · 1982Binding of beta-carbolines and caffeine on benzodiazepine receptors: correlations to convulsions and tremorView study →}

Mechanisms

The load-bearing points are that harman’s MAO-A inhibition is real but weak relative to its methoxylated relatives, and that its toxicological signature (co-mutagenicity, tremor association) — not any therapeutic action — is what earns the moderate flag.

Pharmacokinetics

Harman is a small, lipophilic β-carboline that crosses the blood–brain barrier — consistent with its detection in brain tissue as well as plasma and platelets ^{4Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →}. It is present endogenously and is added to continuously by diet and smoke, so measured body levels reflect a balance of endogenous formation, involuntary intake and clearance rather than a discrete dose. As a MAO-A ligand it interacts with the same enzyme system that clears monoamine neurotransmitters. Detailed human ADME for harman as an isolate — Cmax after a defined intake, half-life, oral bioavailability — is not well characterised; most quantitative work measures steady-state blood or tissue concentrations in exposure and epidemiological studies rather than single-dose kinetics ^{4,8Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →Reference 8Louis ED et al. · 2020ObservationalBlood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe IslandsView study →}.

Clinical Trials

There are no therapeutic clinical trials of harman — it is not developed or taken as a drug. The human literature is observational: case-control studies measuring blood harman in essential tremor and Parkinson’s disease ^{7,8,9Reference 7Louis ED et al. · 2002Elevation of blood beta-carboline alkaloids in essential tremorView study →Reference 8Louis ED et al. · 2020ObservationalBlood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe IslandsView study →Reference 9Louis ED et al. · 2014Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s diseaseView study →}, plus exposure-assessment studies quantifying harman in foods, beverages and tobacco smoke ^{3,5Reference 3Herraiz T · 2004Relative exposure to beta-carbolines norharman and harman from foods and tobacco smokeView study →Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

Harman inverts the usual plant-constituent question. There is essentially no whole-plant therapeutic evidence for harman, because no herb is used for its harman content — in passionflower it is a trace alkaloid (~0.005–0.012% of dried herb), far too low to drive that plant’s mild activity. Instead, almost all harman data are for the isolated molecule or its measured concentration: enzyme-inhibition assays with pure harman ^{1Reference 1Kim H et al. · 1997Inhibition of monoamine oxidase A by beta-carboline derivativesView study →}, receptor-binding studies ^{10,11Reference 10Abu Ghazaleh H et al. · 2015Harmane: an atypical neurotransmitter? Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/25625221/View study →Reference 11Saano V · 1982Binding of beta-carbolines and caffeine on benzodiazepine receptors: correlations to convulsions and tremorView study →}, co-mutagenicity assays ^{6Reference 6Oda Y et al. · 2006Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymesView study →}, and blood/tissue quantification in people ^{7,8,9Reference 7Louis ED et al. · 2002Elevation of blood beta-carboline alkaloids in essential tremorView study →Reference 8Louis ED et al. · 2020ObservationalBlood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe IslandsView study →Reference 9Louis ED et al. · 2014Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s diseaseView study →}. The relevant “exposure vehicle” is not a medicinal plant at all but cooked food and tobacco smoke ^{3,5Reference 3Herraiz T · 2004Relative exposure to beta-carbolines norharman and harman from foods and tobacco smokeView study →Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}. So the isolate-vs-plant caveat here is unusual: the isolate is well-defined, but its real-world context is dietary and environmental rather than herbal.

Prevalence in Nature

Within plants, harman is a minor harmala-type alkaloid. It occurs in Syrian rue (Peganum harmala) alongside the dominant harmine and harmaline, in passionflower (Passiflora incarnata) at trace levels (~0.005–0.012% of the dried herb), in common reed (Phragmites australis), and in puncture vine (Tribulus terrestris), where β-carbolines including harman have been implicated in livestock neurotoxicity. The older synonyms aribine, loturine and passiflorin reflect its repeated independent isolation from different genera in the nineteenth century.

But harman’s true prevalence is outside the plant kingdom. It is a normal endogenous constituent of human (and animal) plasma, platelets and brain ^{4Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →}, and it is generated thermally: in fried and grilled meat and fish, in coffee and roasted foods, in alcoholic drinks, and in tobacco smoke at hundreds to a few thousand nanograms per cigarette ^{3,5Reference 3Herraiz T · 2004Relative exposure to beta-carbolines norharman and harman from foods and tobacco smokeView study →Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}. In practical terms, the largest and most consistent human contact with harman is not botanical — it is the cooked-food and smoke exposure shared by the general population.

Discovery & Synthesis

Harman was first isolated in the nineteenth century as part of the broader characterisation of the harmala alkaloids from Peganum harmala, and independently from other plants under the names aribine (from Ariba/Sickingia bark), loturine and passiflorin — the multiplicity of names reflecting how often this simple, widespread β-carboline turned up in different botanical sources before its structure unified them as 1-methyl-β-carboline. Its later scientific significance came from a different direction: through the twentieth century harman was recognised as an endogenous body constituent and as a pyrolysis product formed whenever tryptophan-rich material is heated, which reframed it from a botanical curiosity into a molecule of dietary and environmental toxicology ^{4,5Reference 4Pfau W · 2004Exposure to beta-carbolines norharman and harmanView study →Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}. As a small β-carboline it is readily prepared synthetically (classically by Pictet–Spengler condensation of tryptamine with an acetaldehyde equivalent followed by aromatisation), and synthetic harman is the standard used in analytical and pharmacological work.

Patents: not yet researched.

Toxicity & Safety

Harman carries a moderate flag — higher than a typical trace plant alkaloid — for three converging reasons: it is a MAO-A inhibitor (so at higher exposure it inherits the interaction cautions of that class), it is associated in human epidemiology with tremor and Parkinson’s disease and is tremorigenic/convulsant at high doses in animals, and it is a co-mutagen that can be bioactivated into DNA-damaging metabolites on pyrolysis. None of this makes ordinary dietary exposure acutely dangerous — background levels are very low — but it is why harman is not a benign inert phytochemical.

Safety at a Glance

⚠️ Moderate toxicity

• Dietary levels are very low. Endogenous and food-borne harman circulates at trace concentrations; there is no evidence of acute harm from ordinary cooked-food or coffee intake.
• MAO-A inhibitor at higher exposure. As a reversible MAO-A inhibitor, harman shares the class caution around combining monoamine-oxidase inhibition with serotonergic drugs or tyramine-rich foods; the risk is concentration-dependent and low at dietary levels.
• Neurological associations. Higher blood harman has been correlated with essential tremor and Parkinson’s disease in case-control studies, and β-carbolines are classically tremorigenic in animals — associations, not proven causation.
• Co-mutagen on pyrolysis. Harman/norharman from charred meat and tobacco smoke can be activated into genotoxic aminophenyl adducts; a reason to favour gentler cooking and to avoid tobacco smoke, not a quantified individual cancer risk.

Full Safety & Interactions Detail

MAO-A inhibition and interactions. Harman is a reversible, MAO-A-selective inhibitor ^{1Reference 1Kim H et al. · 1997Inhibition of monoamine oxidase A by beta-carboline derivativesView study →}. In principle this carries the standard MAO-inhibitor cautions — additive serotonergic risk with SSRIs, SNRIs, triptans and other MAOIs, and a tyramine (“cheese”) interaction — but harman is weaker than harmine/harmaline and dietary exposure is low, so the practical risk at food levels is small. It becomes relevant mainly where β-carboline exposure is high (e.g. concentrated Peganum harmala preparations, which also contain the far more potent harmine and harmaline).

Tremor, convulsions and neurodegeneration. At high doses in animals, harman lowers benzodiazepine-receptor binding and is associated with convulsant/tremorigenic activity ^{11Reference 11Saano V · 1982Binding of beta-carbolines and caffeine on benzodiazepine receptors: correlations to convulsions and tremorView study →}, and the wider β-carboline class is the classic pharmacological trigger of action tremor. In humans, elevated blood harman has been repeatedly correlated with essential tremor ^{7,8Reference 7Louis ED et al. · 2002Elevation of blood beta-carboline alkaloids in essential tremorView study →Reference 8Louis ED et al. · 2020ObservationalBlood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe IslandsView study →} and with Parkinson’s disease ^{9Reference 9Louis ED et al. · 2014Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s diseaseView study →}. These are observational associations: they do not establish harman as a cause, and reverse causation and confounding (diet, smoking, metabolism) are live alternatives.

Genotoxicity / co-mutagenicity. Harman and norharman are co-mutagens and tryptophan-pyrolysis products found in cooked foods and tobacco smoke ^{5Reference 5Totsuka Y et al. · 1999Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foodsView study →}; through adduction with aromatic amines and subsequent NAT/CYP bioactivation they yield DNA-damaging metabolites ^{6Reference 6Oda Y et al. · 2006Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymesView study →}. This is a mechanistic hazard flag rather than a demonstrated human cancer dose-response for harman alone.

Reproductive note (prose only). No dedicated reproductive-toxicity dataset exists for isolated harman; the genotoxic and MAOI properties above are the relevant hazard signals. Pregnancy/lactation decisions belong to the herb or product where intake is actually decided, not to this molecule page — no isolate-level verdict is issued here.

Dosage

Harman has no therapeutic dose — it is not a supplement or medicine, and no one is advised to take it. Human contact is involuntary and low-level, from three sources:

The practical takeaways are dietary, not pharmacological: gentler cooking produces less harman than charring, and avoiding tobacco smoke removes the single most concentrated everyday source. These are exposure and research measurements, not a personal recommendation.

References

1. Kim H, Sablin SO, Ramsay RR (1997). Inhibition of monoamine oxidase A by beta-carboline derivatives. Archives of Biochemistry and Biophysics. https://pubmed.ncbi.nlm.nih.gov/8990278/
2. Saro G, Johne S, Latino DARS, Moine F, van der Toorn M, Mathis C, Veljkovic E (2025). Monoamine oxidase inhibitors present in tobacco modulate dopamine balance via the dopamine transporter. ACS Chemical Neuroscience. https://pubmed.ncbi.nlm.nih.gov/40033845/
3. Herraiz T (2004). Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. Food Additives & Contaminants. https://pubmed.ncbi.nlm.nih.gov/15764332/
4. Pfau W, Skog K (2004). Exposure to beta-carbolines norharman and harman. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/15036003/
5. Totsuka Y, Ushiyama H, Ishihara J, Sinha R, Goto S, Sugimura T, Wakabayashi K (1999). Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods. Cancer Letters. https://pubmed.ncbi.nlm.nih.gov/10503893/
6. Oda Y, Totsuka Y, Wakabayashi K, Guengerich FP, Shimada T (2006). Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymes. Mutagenesis. https://pubmed.ncbi.nlm.nih.gov/17067997/
7. Louis ED, Zheng W, Jurewicz EC, Watner D, Chen J, Factor-Litvak P, Parides M (2002). Elevation of blood beta-carboline alkaloids in essential tremor. Neurology. https://pubmed.ncbi.nlm.nih.gov/12499487/
8. Louis ED, Eliasen EH, Ferrer M, Iglesias Hernandez D, Gaini S, Jiang W, Zheng W, Nielsen F, Petersen MS (2020). Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) and mercury in essential tremor: a population-based, environmental epidemiology study in the Faroe Islands. Neuroepidemiology. https://pubmed.ncbi.nlm.nih.gov/32007995/
9. Louis ED, Michalec M, Jiang W, Factor-Litvak P, Zheng W (2014). Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s disease. Neurotoxicology. https://pubmed.ncbi.nlm.nih.gov/24300779/
10. Abu Ghazaleh H, Lalies MD, Nutt DJ, Hudson AL (2015). Harmane: an atypical neurotransmitter? Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/25625221/
11. Saano V, Airaksinen MM (1982). Binding of beta-carbolines and caffeine on benzodiazepine receptors: correlations to convulsions and tremor. Acta Pharmacologica et Toxicologica. https://pubmed.ncbi.nlm.nih.gov/6295064/

View all 11 references▾